139 related articles for article (PubMed ID: 30723114)
1. Whole Genome-Derived Tiled Peptide Arrays Detect Prediagnostic Autoantibody Signatures in Non-Small-Cell Lung Cancer.
Yan Y; Sun N; Wang H; Kobayashi M; Ladd JJ; Long JP; Lo KC; Patel J; Sullivan E; Albert T; Goodman GE; Do KA; Hanash SM
Cancer Res; 2019 Apr; 79(7):1549-1557. PubMed ID: 30723114
[TBL] [Abstract][Full Text] [Related]
2. Serological proteome analysis approach-based identification of ENO1 as a tumor-associated antigen and its autoantibody could enhance the sensitivity of CEA and CYFRA 21-1 in the detection of non-small cell lung cancer.
Dai L; Qu Y; Li J; Wang X; Wang K; Wang P; Jiang BH; Zhang J
Oncotarget; 2017 May; 8(22):36664-36673. PubMed ID: 28456790
[TBL] [Abstract][Full Text] [Related]
3. Dickkopf-1 autoantibody is a novel serological biomarker for non-small cell lung cancer.
Yao X; Jiang H; Zhang C; Wang H; Yang L; Yu Y; Yu J; Shi B; Shen Z; Gao H; Chen Z; Tian S; Lu S; Li Z; Gu J
Biomarkers; 2010 Mar; 15(2):128-34. PubMed ID: 19839718
[TBL] [Abstract][Full Text] [Related]
4. Serum anti-p53 antibodies in patients with lung cancer.
Mack U; Ukena D; Montenarh M; Sybrecht GW
Oncol Rep; 2000; 7(3):669-74. PubMed ID: 10767388
[TBL] [Abstract][Full Text] [Related]
5. An Autoantibody Against Human DNA-Topoisomerase I Is a Novel Biomarker for Non-Small Cell Lung Cancer.
Wu WB; Yie SM; Ye SR; Xie K; Zhang JB; Cao M; Chen J; He X; Ma XL; Zhang J
Ann Thorac Surg; 2018 Jun; 105(6):1664-1670. PubMed ID: 29453962
[TBL] [Abstract][Full Text] [Related]
6. Clinical implications of p53 autoantibodies in the sera of patients with non-small-cell lung cancer.
Mitsudomi T; Suzuki S; Yatabe Y; Nishio M; Kuwabara M; Gotoh K; Hatooka S; Shinoda M; Suyama M; Ogawa M; Takahashi T; Ariyoshi Y; Takahashi T
J Natl Cancer Inst; 1998 Oct; 90(20):1563-8. PubMed ID: 9790550
[TBL] [Abstract][Full Text] [Related]
7. Development of autoantibody signatures as novel diagnostic biomarkers of non-small cell lung cancer.
Wu L; Chang W; Zhao J; Yu Y; Tan X; Su T; Zhao L; Huang S; Liu S; Cao G
Clin Cancer Res; 2010 Jul; 16(14):3760-8. PubMed ID: 20501620
[TBL] [Abstract][Full Text] [Related]
8. Performance of a multiplexed dual analyte immunoassay for the early detection of non-small cell lung cancer.
Doseeva V; Colpitts T; Gao G; Woodcock J; Knezevic V
J Transl Med; 2015 Feb; 13():55. PubMed ID: 25880432
[TBL] [Abstract][Full Text] [Related]
9. Presence of serum anti-p53 antibodies is associated with pleural effusion and poor prognosis in lung cancer patients.
Lai CL; Tsai CM; Tsai TT; Kuo BI; Chang KT; Fu HT; Perng RP; Chen JY
Clin Cancer Res; 1998 Dec; 4(12):3025-30. PubMed ID: 9865916
[TBL] [Abstract][Full Text] [Related]
10. Complement factor H autoantibodies are associated with early stage NSCLC.
Amornsiripanitch N; Hong S; Campa MJ; Frank MM; Gottlin EB; Patz EF
Clin Cancer Res; 2010 Jun; 16(12):3226-31. PubMed ID: 20515868
[TBL] [Abstract][Full Text] [Related]
11. High-Throughput Peptide Arrays Identify Potential Diagnostic Autoantibody Signatures in Early-Stage Lung Adenocarcinoma.
Luo R; Zhong P; Li X; Cai J; Tao Y; Xiong B; Zheng H; Zhang Z; Tang L; Yao J; Li Y; Shi Y; Han X
Cancer Epidemiol Biomarkers Prev; 2023 May; 32(5):726-738. PubMed ID: 36857775
[TBL] [Abstract][Full Text] [Related]
12. Detection of autoantibodies against cancer-testis antigens in non-small cell lung cancer.
Djureinovic D; Dodig-Crnković T; Hellström C; Holgersson G; Bergqvist M; Mattsson JSM; Pontén F; Ståhle E; Schwenk JM; Micke P
Lung Cancer; 2018 Nov; 125():157-163. PubMed ID: 30429015
[TBL] [Abstract][Full Text] [Related]
13. Gene mutation analysis in non-small cell lung cancer patients using bronchoalveolar lavage fluid and tumor tissue as diagnostic markers.
Li J; Hu YM; Wang Y; Tang XP; Shi WL; Du YJ
Int J Biol Markers; 2014 Dec; 29(4):e328-36. PubMed ID: 24519547
[TBL] [Abstract][Full Text] [Related]
14. The role of circulating anti-p53 antibodies in patients with advanced non-small cell lung cancer and their correlation to clinical parameters and survival.
Bergqvist M; Brattström D; Larsson A; Hesselius P; Brodin O; Wagenius G
BMC Cancer; 2004 Sep; 4():66. PubMed ID: 15367333
[TBL] [Abstract][Full Text] [Related]
15. Integrated analysis of the prognostic value of TP53 dependent etoposide-induced gene 24 in non-small cell lung cancer.
Wang M; Li P; Wan R; Liu X
Biomed Pharmacother; 2019 Apr; 112():108590. PubMed ID: 30784913
[TBL] [Abstract][Full Text] [Related]
16. Using whole genome amplification (WGA) of low-volume biopsies to assess the prognostic role of EGFR, KRAS, p53, and CMET mutations in advanced-stage non-small cell lung cancer (NSCLC).
Lim EH; Zhang SL; Li JL; Yap WS; Howe TC; Tan BP; Lee YS; Wong D; Khoo KL; Seto KY; Tan L; Agasthian T; Koong HN; Tam J; Tan C; Caleb M; Chang A; Ng A; Tan P
J Thorac Oncol; 2009 Jan; 4(1):12-21. PubMed ID: 19096301
[TBL] [Abstract][Full Text] [Related]
17. Serum Protein Markers for the Early Detection of Lung Cancer: A Focus on Autoantibodies.
Broodman I; Lindemans J; van Sten J; Bischoff R; Luider T
J Proteome Res; 2017 Jan; 16(1):3-13. PubMed ID: 27769114
[TBL] [Abstract][Full Text] [Related]
18. [A Novel Method for Detecting p53 Autoantibodies in Sera of Patients with NSCLC.].
Tang K; Yue W; Wang Y; Zhang L; Xu S
Zhongguo Fei Ai Za Zhi; 2009 Sep; 12(9):969-74. PubMed ID: 20719194
[TBL] [Abstract][Full Text] [Related]
19. Enhancement of a multianalyte serum biomarker panel to identify lymph node metastases in non-small cell lung cancer with circulating autoantibody biomarkers.
Patel K; Farlow EC; Kim AW; Lee BS; Basu S; Coon JS; DeCresce D; Thimothy L; Walters KA; Fhied C; Chang C; Chen SH; Faber LP; Bonomi P; Liptay MJ; Borgia JA
Int J Cancer; 2011 Jul; 129(1):133-42. PubMed ID: 20824709
[TBL] [Abstract][Full Text] [Related]
20. Significance of tumor-associated autoantibodies in the early diagnosis of lung cancer.
Du Q; Yu R; Wang H; Yan D; Yuan Q; Ma Y; Slamon D; Hou D; Wang H; Wang Q
Clin Respir J; 2018 Jun; 12(6):2020-2028. PubMed ID: 29356386
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
